Inhibrx Biosciences (INBX) Current Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Current Leases data on file, last reported at $2.3 million in Q4 2025.

• On a quarterly basis, Current Leases rose 45.83% year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $2.3 million, a 45.83% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 45.83% from the prior year.
• Current Leases for Q4 2025 stood at $2.3 million, up from $2.2 million in the prior quarter.
• Over the last five years, Current Leases for INBX reached as high as $2.3 million in Q4 2025 and fell as low as $1.6 million in Q4 2024.
• Historically, Current Leases has averaged $2.0 million across 3 years, with a median of $2.1 million in 2023.
• Across the five-year window, Current Leases retreated 22.69% in 2024 and soared 45.83% in 2025, its largest moves.
• Year by year, Current Leases stood at $2.1 million in 2023, then fell by 22.69% to $1.6 million in 2024, then jumped by 45.83% to $2.3 million in 2025.
• Per Business Quant data, the three most recent Current Leases figures were $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.2 million in Q2 2025.